Panelists discuss how they currently utilize emerging ctDNA platforms for high-risk patients and explore whether these advancements will soon become standard practice in clinical decision-making.
Knowing that your patient is high risk and that will be important, and we have all this ctDNA and more platforms emerging, how are you using the platforms at present? Do you foresee the time will be soon enough?